Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية الصباغ - sabbagh drug store - fulvestrant 250 mg/5ml - 250 mg/5ml

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

mylan pharmaceuticals (pty) ltd - #n/a - not indicated - none

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - fulvestrant 50 mg/ml;   - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml   excipient: benzyl alcohol benzyl benzoate castor oil ethanol - faslodex is indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age: - not previously treated with endocrine therapy, or - previously treated with endocrine therapy (antioestrogen or aromatase inhibitor) therapy, irrespective of whether their postmenopausal status occurred naturally or was artificially induced.

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - breast neoplasms - endocrine therapy, anti-estrogens - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy., , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. , in pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinizing hormone releasing hormone (lhrh) agonist.,

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - fulvestrant 50 mg/ml - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml excipient: benzyl alcohol benzyl benzoate castor oil ethanol - indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age, previously treated with endocrine therapy (antioestrogen or aromatase inhibitor therapy), irrespective of whether their postmenopausal status occurred naturally or was artificially induced.

New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - fulvestrant 50 mg/ml - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml excipient: benzyl alcohol benzyl benzoate castor oil ethanol - indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age, previously treated with endocrine therapy (antioestrogen or aromatase inhibitor therapy), irrespective of whether their postmenopausal status occurred naturally or was artificially induced.

Canada - English - Health Canada

astrazeneca canada inc - fulvestrant - solution - 50mg - fulvestrant 50mg - antineoplastic agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astrazeneca uk ltd - fulvestrant - solution for injection - 50mg/1ml

Singapore - English - HSA (Health Sciences Authority)

euro asia medico pte. ltd. - fulvestrant - injection, solution - fulvestrant 250mg / 5ml

Israel - English - Ministry of Health

bioavenir ltd, israel - fulvestrant - solution for injection - fulvestrant 50 mg/ml - fulvestrant - monotherapy :fulvenir is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:not previously treated with endocrine therapy, or with disease relapse on or after adjuvant endocrine therapy; or disease progression on endocrine therapy. combination therapy with palbociclib: fulvenir is indicated for the treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.